5 results for "T. Quaranta"
Showing 1–5 · 3.09 seconds · RSS
-
Journal Article
P115 | CUTANEOUS INVOLVEMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-WORLD OUTCOMES WITH VENETOCLAX-OBINUTUZUMAB AT FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS.
Introduction: Cutaneous manifestations are rare in patients with chronic lymphocytic leukaemia (CLL) and may result from either direct leukemic infiltration or the general predisposition of CLL patients to secondary conditions. Leukaemia cutis (LC), caused by skin infiltration of leukemic cells, is…
-
Journal Article
P123 | IBRUTINIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OUTSIDE CLINICAL TRIALS: A SINGLE-CENTER REAL-WORLD EXPERIENCE
Introduction: The combination of ibrutinib, a Bruton's tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, has shown synergistic efficacy in chronic lymphocytic leukemia (CLL). Pivotal trials like CAPTIVATE and GLOW report high rates of complete remission (CR) and undetectable minimal…
-
Journal Article
P106 | ONCOGERIATRIC ASSESSMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OVER 65 YEARS IN TARGET ERA. A MONOCENTRIC PILOT STUDY AT FONDAZIONE POLICLINICO A. GEMELLI, ROME
Introduction: Chronic lymphocytic leukemia (CLL) primarily affects elderly adults. While targeted agents such as BTKi and BCL-2 inhibitors have improved outcomes, their use in elderly patients raises concerns regarding tolerance and toxicity, and there is still no established method for defining…
-
Journal Article
P120 | CHRONIC LYMPHOCYTIC LEUKEMIA AND RENAL CELL CARCINOMA: A CASE SERIES OF TWELVE PATIENTS
Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with a median age at diagnosis of 72 years. CLL patients (pts) have an increased risk of second malignancies due to multiple synergistic factors: genetic, environmental, treatment-induced and immunomodulatory…
-
Journal Article
DP046 | ABSENCE OF LYMPHOCYTOSIS INCREASE AFTER STARTING TREATMENT WITH CBTKI IS UNUSUAL AND ASSOCIATED TO SPECIFIC BIOLOGICAL MARKERS
Background: Bruton tyrosine kinase inhibitors (BTKi) are a class of drugs that have revolutionized Chronic Lymphocytic Leukemia (CLL) therapy. They inhibit Bruton tyrosine kinase (BTK), an enzyme able to trigger a lot of metabolic ways involved in B lymphocytes surviving, proliferation and…